Brief: G1 Therapeutics Says Results From Phase 2 Trial Confirm Benefit Of Trilaciclib In Reducing Adverse Events Related To Antibody Drug Conjugate

G1 Therapeutics

10/05/2023 12:34

May 10 (Reuters) - G1 Therapeutics Inc  GTHX.O :
    * NEW RESULTS FROM PHASE 2 TRIAL CONFIRM BENEFIT OF
TRILACICLIB IN
REDUCING ADVERSE EVENTS RELATED TO AN ANTIBODY DRUG CONJUGATE
(ADC)
    * G1 THERAPEUTICS INC: OVERALL SURVIVAL (OS) RESULTS ARE
CURRENTLY
EXPECTED IN Q1 OF 2024
    * G1 THERAPEUTICS INC: ON-TARGET EFFECT OF TRILACICLIB
REDUCES
RATES OF MULTIPLE ADVERSE EVENTS ASSOCIATED WITH SACITUZUMAB
GOVITECAN-HZIY BY OVER 50%
    * G1 THERAPEUTICS: INITIAL OBJECTIVE RESPONSE RATE IN STUDY
POPULATION CONSISTENT WITH ORR IN CHECKPOINT INHIBITOR
PRETREATED POPULATION IN ASCENT TRIAL

Source text for Eikon:  ID:nGNXbdFJTy 
Further company coverage:  GTHX.O 

 ((Reuters.Briefs@thomsonreuters.com;))